Biogen Inc. (BIIB) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Biogen Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Biogen Inc. (BIIB) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $37.3B. It trades at $244.05, down 3.43% today, at 43.2 times earnings. Its overall quality score is 48 out of 100, ranked against the whole US market. 23 analysts' average target of $249.91 implies +2.4% from today's price. Kronos AI's 30-day forecast is −19.1% (0 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $249.91 |
| Low – high | $175.00 – $325.00 |
| Analysts | 23 |
| Upside to average | +2.4% |
Kronos AI 30-day forecast
| Expected close | $204.54 (−19.1%) |
| Likely range | −19.8% … −17.5% |
| As of | 2026-10-27 |
Quality scores
| Profitability | 61 |
| Solvency | 48 |
| Growth | 34 |
| Overall | 48 |
| P/E | 43.2 |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Halal Health Care stocks · Zakat calculator · Purification calculator